Researchers and clinical teams reported that menin inhibitors continue to emerge as the leading targeted approach for KMT2A‑rearranged acute leukemias, a historically treatment‑resistant subset. New preclinical and early clinical data cited in the review show on‑target activity, leukemic blast differentiation and combination potential with epigenetic agents. Teams emphasize activity in pediatric and young‑adult cohorts where KMT2A rearrangements are most common. Investigators highlighted biomarkers of response and resistance, and outlined development pathways for regulatory submission. Companies developing menin inhibitors are moving toward registration‑directed trials and combination studies; the work signals a likely shift in standard‑of‑care trials for KMT2A‑driven disease.